NewAmsterdam Pharma (NAMS) Income towards Parent Company (2023 - 2025)
Historic Income towards Parent Company for NewAmsterdam Pharma (NAMS) over the last 3 years, with Q3 2025 value amounting to -$72.0 million.
- NewAmsterdam Pharma's Income towards Parent Company fell 33254.04% to -$72.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$221.1 million, marking a year-over-year decrease of 1115.4%. This contributed to the annual value of -$241.6 million for FY2024, which is 3654.46% down from last year.
- Latest data reveals that NewAmsterdam Pharma reported Income towards Parent Company of -$72.0 million as of Q3 2025, which was down 33254.04% from -$17.4 million recorded in Q2 2025.
- NewAmsterdam Pharma's Income towards Parent Company's 5-year high stood at -$16.6 million during Q3 2024, with a 5-year trough of -$93.8 million in Q1 2024.
- Moreover, its 3-year median value for Income towards Parent Company was -$44.6 million (2023), whereas its average is -$50.9 million.
- As far as peak fluctuations go, NewAmsterdam Pharma's Income towards Parent Company skyrocketed by 6468.08% in 2024, and later plummeted by 33254.04% in 2025.
- Quarter analysis of 3 years shows NewAmsterdam Pharma's Income towards Parent Company stood at -$49.5 million in 2023, then plummeted by 86.34% to -$92.2 million in 2024, then increased by 21.88% to -$72.0 million in 2025.
- Its last three reported values are -$72.0 million in Q3 2025, -$17.4 million for Q2 2025, and -$39.5 million during Q1 2025.